Search

Search Constraints

You searched for: Author/Creator Yanagitani, Noriko

Search Results

21. Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). (May 2023)

22. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer. Issue 3 (13th January 2020)

23. Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma. (19th August 2020)

24. Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma. (19th August 2020)

25. Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation. Issue 5 (June 2015)

26. Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation. Issue 5 (June 2015)

27. Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases. Issue 9 (12th July 2020)

28. Prognostic value of 18F‐fluoroazomycin arabinoside PET/CT in patients with advanced non‐small‐cell lung cancer. Issue 11 (7th October 2015)

29. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer. (March 2016)

30. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer. (March 2016)